DK1565201T3 - Fremgangsmåder til at administrere dalbavancin til behandling af bakterieinfektioner - Google Patents
Fremgangsmåder til at administrere dalbavancin til behandling af bakterieinfektioner Download PDFInfo
- Publication number
- DK1565201T3 DK1565201T3 DK03789744.4T DK03789744T DK1565201T3 DK 1565201 T3 DK1565201 T3 DK 1565201T3 DK 03789744 T DK03789744 T DK 03789744T DK 1565201 T3 DK1565201 T3 DK 1565201T3
- Authority
- DK
- Denmark
- Prior art keywords
- dalbavancin
- dose
- solution
- administered
- binding
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/14—Peptides containing saccharide radicals; Derivatives thereof, e.g. bleomycin, phleomycin, muramylpeptides or vancomycin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
- A61K31/7034—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin
- A61K31/704—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin attached to a condensed carbocyclic ring system, e.g. sennosides, thiocolchicosides, escin, daunorubicin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Epidemiology (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Immunology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Gastroenterology & Hepatology (AREA)
- Organic Chemistry (AREA)
- Oncology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Communicable Diseases (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Peptides Or Proteins (AREA)
Claims (16)
1. Anvendelse af dalbavancin i fremstillingen af et medikament til anvendelse i en fremgangsmåde til behandling afen bakterieinfektion hos et menneske med behov derfor, hvilken fremgangsmåde omfatter: at administrere indledende og efterfølgende terapeutisk effektive doser af dalbavancin i en farmaceutisk acceptabel bærer til patienten, hvor hver dosis er adskilt med fem til ti dage og hvor mængden af den indledende dosis er 500 mg til 5000 mg, og hvor mængden af den indledende dosis er mindst omkring to gange mængden af dalbavancin indeholdt i den efterfølgende dosis.
2. Anvendelse af dalbavancin i fremstillingen af et medikament til anvendelse i en fremgangsmåde til behandling afen bakterieinfektion hos et menneske med behov derfor, hvilken fremgangsmåde omfatter: at administrere indledende og efterfølgende terapeutisk effektive doser af dalbavancin i en farmaceutisk acceptabel bærer til patienten, hvor hver dosis er adskilt med omkring en uge og hvor mængden af den indledende dosis er 1000 mg og mængden af hver efterfølgende dosis er 500 mg.
3. Anvendelsen ifølge krav 1, hvor hver dosis er adskilt med fem til ti dage og hvor mængden af den indledende dosis er 500 mg til 5000 mg og mængden af hver efterfølgende dosis er 250 mg til 2500 mg.
4. Anvendelsen ifølge et hvilket som helst af kravene 1 til 3, hvor fremgangsmåden omfatter at administrere en enkelt efterfølgende dosis.
5. Anvendelsen ifølge et hvilket som helst af kravene 1 til 3, hvor fremgangsmåden omfatter at administrere flere efterfølgende doser.
6. Anvendelsen ifølge krav 1 eller krav 2, hvor bakterieinfektionen er en hud- og blødt væv-infektion.
7. Anvendelsen ifølge krav 3, hvor bakterieinfektionen er en hud- og blødt vævinfektion.
8. Anvendelsen ifølge krav 7, hvor bakterieinfektionen er en kompliceret hud- og blødt væv-infektion.
9. Anvendelsen ifølge krav 7, hvor bakterieinfektionen er en ukompliceret hud- og blødt væv-infektion.
10. Farmaceutisk sammensætning omfattende: dalbavancin; og et stabiliseringsmiddel, hvor stabiliseringsmidlet omfatter mannitol og laktose.
11. Den farmaceutiske sammensætning ifølge krav 10, hvor vægtforholdet af mannitol:laktose:dalbavancin er 1:1:4.
12. Den farmaceutiske sammensætning ifølge krav 10, hvor den farmaceutiske sammensætning har en pH på omkring 3 til 5.
13. Den farmaceutiske sammensætning ifølge krav 10, hvor den farmaceutiske sammensætning har en pH på omkring 4,5.
14. Farmaceutisk sammensætning omfattende: dalbavancin; og et stabiliseringsmiddel, hvor stabiliseringsmidlet omfatter mannitol ved en pH på 3-5.
15. Den farmaceutiske sammensætning ifølge krav 14, hvor pH er omkring 3,5.
16. Den farmaceutiske sammensætning ifølge krav 14, hvor vægtforholdet af mannitohdalbavancin er 1:2.
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US42765402P | 2002-11-18 | 2002-11-18 | |
| US48569403P | 2003-07-08 | 2003-07-08 | |
| US49504803P | 2003-08-13 | 2003-08-13 | |
| US49648303P | 2003-08-19 | 2003-08-19 | |
| PCT/US2003/036127 WO2004045636A1 (en) | 2002-11-18 | 2003-11-14 | Methods of administering dalbavancin for treatment of bacterial infections |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| DK1565201T3 true DK1565201T3 (da) | 2019-02-25 |
Family
ID=32330046
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| DK03789744.4T DK1565201T3 (da) | 2002-11-18 | 2003-11-14 | Fremgangsmåder til at administrere dalbavancin til behandling af bakterieinfektioner |
Country Status (15)
| Country | Link |
|---|---|
| US (12) | US20050130909A1 (da) |
| EP (1) | EP1565201B1 (da) |
| JP (3) | JP5519090B2 (da) |
| KR (2) | KR20120056310A (da) |
| AU (3) | AU2003298662A1 (da) |
| CA (1) | CA2506236C (da) |
| DK (1) | DK1565201T3 (da) |
| ES (1) | ES2712656T3 (da) |
| HK (2) | HK1083684A1 (da) |
| HU (1) | HUE041133T2 (da) |
| IL (3) | IL168327A (da) |
| MX (1) | MXPA05005338A (da) |
| NO (1) | NO20052362L (da) |
| PT (1) | PT1565201T (da) |
| WO (3) | WO2004045636A1 (da) |
Families Citing this family (24)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7119061B2 (en) * | 2002-11-18 | 2006-10-10 | Vicuron Pharmaceuticals, Inc. | Dalbavancin compositions for treatment of bacterial infections |
| HUE041133T2 (hu) | 2002-11-18 | 2019-05-28 | Vicuron Pharmaceuticals Llc | Dalbavancin adagolási módszer bakteriális fertõzések kezelésére |
| US20060074014A1 (en) * | 2002-11-18 | 2006-04-06 | Vicuron Pharmaceuticals Inc. | Dalbavancin compositions for treatment of bacterial infections |
| US20090062182A1 (en) * | 2007-08-29 | 2009-03-05 | Protia, Llc | Deuterium-enriched dalbavancin |
| US8389583B2 (en) * | 2008-05-23 | 2013-03-05 | Zurex Pharma, Inc. | Antimicrobial compositions and methods of use |
| US20110132607A1 (en) * | 2009-12-07 | 2011-06-09 | Schlumberger Technology Corporation | Apparatus and Technique to Communicate With a Tubing-Conveyed Perforating Gun |
| TWI641372B (zh) | 2013-03-15 | 2018-11-21 | 美商梅琳塔有限責任公司 | 使用抗生素治療超重和肥胖患者感染的方法 |
| EP3084276B1 (en) | 2013-12-19 | 2019-07-17 | GE Healthcare Bio-Sciences AB | Remotely actuated valve for a biological liquid treatment system |
| EP3169345A4 (en) * | 2014-07-17 | 2018-01-17 | The Medicines Company | High purity oritavancin and method of producing same |
| RS59851B1 (sr) | 2014-11-06 | 2020-02-28 | Xellia Pharmaceuticals Aps | Kompozicije glikopeptida |
| WO2016140981A1 (en) * | 2015-03-02 | 2016-09-09 | Colonaryconcepts Llc | Compounds and methods for peg metabolite and peg breakdown product assays |
| US10071141B2 (en) | 2015-05-08 | 2018-09-11 | Spectral Platforms, Inc. | Albumin-based non-covalent complexes and methods of use thereof |
| WO2017179003A1 (en) | 2016-04-15 | 2017-10-19 | Lupin Limited | Topical compositions for ophthalmic and otic use |
| WO2018175346A1 (en) | 2017-03-20 | 2018-09-27 | Spectral Platforms, Inc. | Spectroscopic methods to detect and characterize microorganisms |
| CN111295183A (zh) * | 2017-07-10 | 2020-06-16 | 康特拉费克特公司 | 裂解蛋白抗菌活性的血液组分强化及其方法和用途 |
| CN110183519B (zh) * | 2019-05-06 | 2023-04-11 | 大邦(湖南)生物制药有限公司 | 一种达巴万星关键中间体a40926的分离纯化方法 |
| CN112480214B (zh) * | 2020-12-14 | 2023-03-28 | 成都雅途生物技术有限公司 | 一种达巴万星关键中间体a40926的制备方法 |
| EP4014965A1 (en) | 2020-12-16 | 2022-06-22 | EVER Valinject GmbH | Aqueous solution |
| CA3204571A1 (en) | 2021-01-11 | 2022-07-14 | Vidar Bjornstad | Synthesis process |
| CN115215926A (zh) * | 2022-08-12 | 2022-10-21 | 丽珠集团福州福兴医药有限公司 | 达巴万星母核及其纯化方法、达巴万星及其合成方法 |
| WO2024079224A1 (en) * | 2022-10-12 | 2024-04-18 | Xellia Pharmaceuticals Aps | Liquid dalbavancin composition |
| WO2024079223A1 (en) * | 2022-10-12 | 2024-04-18 | Xellia Pharmaceuticals Aps | Liquid dalbavancin composition |
| EP4431084A1 (en) | 2023-03-16 | 2024-09-18 | Adalvo Limited | Formulation of dalbavancin |
| EP4431083A1 (en) | 2023-03-16 | 2024-09-18 | Adalvo Limited | Formulation of dalbavancin |
Family Cites Families (56)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US573679A (en) * | 1896-12-22 | Apparatus for mowing hay | ||
| US541616A (en) * | 1895-06-25 | Elevator attachment | ||
| GB1496386A (en) * | 1975-03-05 | 1977-12-30 | Lepetit Spa | Antibiotics |
| US4195079A (en) * | 1979-01-31 | 1980-03-25 | Pfizer Inc. | New polycyclic ether antibiotic |
| CA1183789A (en) | 1981-08-04 | 1985-03-12 | Kiyoshi Isono | Antibiotic 76-11, process for the production thereof, anticoccidiosis agent and domestic animals growth accelerator comprising the same as an effective ingredient |
| US4578271A (en) | 1982-05-24 | 1986-03-25 | Fujisawa Pharmaceutical Co., Ltd. | Biologically active WS 6049 substances, a process for the production thereof and their pharmaceutical compositions |
| FI73697C (fi) | 1982-06-08 | 1987-11-09 | Lepetit Spa | Foerfarande foer framstaellning av individuella faktorer 1, 2, 3, 4 och 5 av teikomysin a2. |
| FR2548021B1 (fr) | 1983-06-29 | 1986-02-28 | Dick P R | Compositions pharmaceutiques dermiques a action prolongee et continue a base d'acides gras essentiels |
| GB8415092D0 (en) * | 1984-06-13 | 1984-07-18 | Lepetit Spa | Ester derivatives |
| GB8425685D0 (en) | 1984-10-11 | 1984-11-14 | Lepetit Spa | Antibiotic a 40926 complex |
| GB8428619D0 (en) * | 1984-11-13 | 1984-12-19 | Lepetit Spa | Derivatives of antibiotic l 17046 |
| US4914187A (en) * | 1984-11-13 | 1990-04-03 | Gruppo Lepetit S.P.A | Ester derivatives of antibiotic L 17046 |
| GB8512795D0 (en) | 1985-05-21 | 1985-06-26 | Lepetit Spa | Increasing ratio of components of teicoplanin a2 complex |
| GB8531846D0 (en) | 1985-12-30 | 1986-02-05 | Lepetit Spa | Antibiotic a 40926 mannosyl aglycon |
| GB8608809D0 (en) * | 1986-04-11 | 1986-05-14 | Lepetit Spa | Antibiotic |
| GB8621912D0 (en) * | 1986-09-11 | 1986-10-15 | Lepetit Spa | Increasing ratio of components of anti-biotic complex |
| GB8621911D0 (en) | 1986-09-11 | 1986-10-15 | Lepetit Spa | Increasing ratio of components of anti-biotic complex |
| GR871488B (en) | 1986-10-10 | 1987-11-12 | Lepetit Spa | New antibiotics |
| GB8715735D0 (en) * | 1987-07-03 | 1987-08-12 | Lepetit Spa | De-mannosyl teicoplanin derivatives |
| US4882313A (en) | 1987-07-31 | 1989-11-21 | Smithkline Beckman Corporation | Carboxamide derivatives of glycopeptides |
| GB8726859D0 (en) | 1987-11-17 | 1987-12-23 | Lepetit Spa | 22-dechlorotei-coplanins |
| US5004605A (en) * | 1987-12-10 | 1991-04-02 | Cetus Corporation | Low pH pharmaceutical compositions of recombinant β-interferon |
| FR2628269B1 (fr) * | 1988-03-04 | 1990-07-27 | Sgs Thomson Microelectronics | Dispositif de demarrage progressif d'une alimentation a decoupage |
| EP0376041B1 (en) | 1988-12-27 | 1996-02-28 | GRUPPO LEPETIT S.p.A. | C63-Amide derivatives of 34-de(acetylglucosaminyl)-34-deoxy-teicoplanins |
| IE64155B1 (en) | 1989-03-29 | 1995-07-12 | Lepetit Spa | New substituted alkylamide derivatives of teicoplanin |
| JPH03193735A (ja) | 1989-12-22 | 1991-08-23 | Shionogi & Co Ltd | グリコペプチド系抗生物質の安定化組成物 |
| US5030619A (en) * | 1990-04-16 | 1991-07-09 | Miles Inc. | Synergistic fungicidal composition |
| US5606036A (en) | 1991-03-27 | 1997-02-25 | Gruppo Lepetit Spa | Antibiotic A 40926 ester derivatives |
| JP2783722B2 (ja) * | 1991-07-12 | 1998-08-06 | 麒麟麦酒株式会社 | スピカマイシン誘導体およびそれを含む抗腫瘍剤 |
| UA41283C2 (uk) | 1991-07-29 | 2001-09-17 | Біосерч Італіа С.П.А. | Похідні антибіотику а 40926 та способи їх одержання |
| US5750509A (en) * | 1991-07-29 | 1998-05-12 | Gruppo Lepetit S.P.A. | Amide derivatives of antibiotic A 40926 |
| US6384013B1 (en) * | 1992-03-19 | 2002-05-07 | Eli Lilly And Company | Cyclic peptide antifungal agents and process for preparation thereof |
| US5882900A (en) | 1992-09-10 | 1999-03-16 | Gruppo Lepetit S.P.A. | Process for the selective increase of production of antibiotic GE 2270 factor a by adding vitamin B12 to nutrient medium |
| CA2112776C (en) * | 1993-01-21 | 2002-11-12 | Masakazu Tsuchiya | Process for inhibiting activity of endotoxin |
| JP3555952B2 (ja) * | 1993-04-30 | 2004-08-18 | バイオグノスティック・ゲゼルシャフト・フュア・バイオモレキュラーレ・ダイアグノスティック・ミット・ベシュレンクテル・ハフツング | トランスフォーミング成長因子−β（ＴＧＦ‐β）の免疫抑制効果の治療用アンチセンス−オリゴヌクレオチド類 |
| SI9500039B (sl) * | 1995-02-07 | 2002-02-28 | Lek, | Nov kombiniran postopek čiščenja Vankomicin hidroklorida |
| WO1996024608A1 (en) * | 1995-02-07 | 1996-08-15 | Biosearch Italia S.P.A. | Basic oxazoline-amide derivatives of ge 2270 and ge 2270-like antibiotics |
| EP0801655B1 (en) | 1995-02-07 | 1998-04-15 | Biosearch Italia S.p.A. | Basic proline-amide derivatives of ge 2270 and ge 2270-like antibiotics |
| US5789308A (en) * | 1995-06-06 | 1998-08-04 | Advanced Micro Devices, Inc. | Manufacturing method for wafer slice starting material to optimize extrinsic gettering during semiconductor fabrication |
| CA2180206A1 (en) * | 1995-06-30 | 1996-12-31 | Motoya Ohshika | Freeze-dried preparation for pharmaceutical use |
| ES2224173T3 (es) * | 1995-07-05 | 2005-03-01 | Aventis Bulk S.P.A. | Purificacion de antibioticos dalbaheptidos por enfoque isoelectrico. |
| DE19600590A1 (de) * | 1996-01-10 | 1997-07-24 | Tzn Forschung & Entwicklung | Schutzvorrichtung für optische Systeme zur Vermeidung von Schäden bei Bestrahlung dieser Systeme mit Laserlicht |
| AU714958B2 (en) | 1996-02-14 | 2000-01-13 | Vicuron Pharmaceuticals Inc. | Derivatives of antibiotic GE2270 factors C2a D2 and E |
| WO1997038702A1 (en) | 1996-04-12 | 1997-10-23 | Eli Lilly And Company | Covalently-linked glycopeptide dimers |
| EP0912604B1 (en) * | 1996-04-23 | 2001-11-14 | Biosearch Italia S.p.A. | Improved chemical process for preparing amide derivatives of antibiotic A 40926 |
| US5935238A (en) * | 1997-06-19 | 1999-08-10 | Sun Microsystems, Inc. | Selection from multiple fetch addresses generated concurrently including predicted and actual target by control-flow instructions in current and previous instruction bundles |
| JP4204655B2 (ja) * | 1997-08-08 | 2009-01-07 | 株式会社ルネサステクノロジ | パルス出力機能付マイクロコンピュータ |
| EP0931834A3 (en) | 1997-12-23 | 2002-06-26 | Eli Lilly And Company | Echinocandin binding domain of 1,3-Beta-glucan synthase |
| US6541616B1 (en) * | 1998-10-01 | 2003-04-01 | Antex Biologics Inc. | Moraxella catarrhalis protein, gene sequence and uses thereof |
| US6417180B1 (en) | 1998-10-07 | 2002-07-09 | University Of Massachusetts | Zinc finger-reactive antimicrobial compounds |
| HU230190B1 (hu) * | 1998-12-23 | 2015-09-28 | Theravance, Inc | Glikopeptidszármazékok és ezeket tartalmazó gyógyászati kompozíciók |
| TWI233805B (en) * | 1999-07-01 | 2005-06-11 | Fujisawa Pharmaceutical Co | Stabilized pharmaceutical composition in lyophilized form as antifungal agent |
| AU2001259298A1 (en) | 2000-05-02 | 2001-11-12 | Advanced Medicine, Inc. | Polyacid glycopeptide derivatives |
| AU2003229475A1 (en) | 2002-02-18 | 2003-09-09 | Combinature Biopharm Ag | Novel glycopeptide antibiotics and method for synthesis thereof |
| US7119061B2 (en) * | 2002-11-18 | 2006-10-10 | Vicuron Pharmaceuticals, Inc. | Dalbavancin compositions for treatment of bacterial infections |
| HUE041133T2 (hu) * | 2002-11-18 | 2019-05-28 | Vicuron Pharmaceuticals Llc | Dalbavancin adagolási módszer bakteriális fertõzések kezelésére |
-
2003
- 2003-11-14 HU HUE03789744A patent/HUE041133T2/hu unknown
- 2003-11-14 KR KR1020127012832A patent/KR20120056310A/ko not_active Application Discontinuation
- 2003-11-14 MX MXPA05005338A patent/MXPA05005338A/es active IP Right Grant
- 2003-11-14 AU AU2003298662A patent/AU2003298662A1/en not_active Abandoned
- 2003-11-14 US US10/714,166 patent/US20050130909A1/en not_active Abandoned
- 2003-11-14 JP JP2004570384A patent/JP5519090B2/ja not_active Expired - Lifetime
- 2003-11-14 US US10/714,261 patent/US6900175B2/en active Active
- 2003-11-14 AU AU2003299561A patent/AU2003299561A1/en not_active Abandoned
- 2003-11-14 EP EP03789744.4A patent/EP1565201B1/en not_active Expired - Lifetime
- 2003-11-14 WO PCT/US2003/036127 patent/WO2004045636A1/en active Application Filing
- 2003-11-14 WO PCT/US2003/036399 patent/WO2004046196A2/en not_active Application Discontinuation
- 2003-11-14 AU AU2003294262A patent/AU2003294262B2/en not_active Expired
- 2003-11-14 DK DK03789744.4T patent/DK1565201T3/da active
- 2003-11-14 ES ES03789744T patent/ES2712656T3/es not_active Expired - Lifetime
- 2003-11-14 WO PCT/US2003/036779 patent/WO2004045637A1/en not_active Application Discontinuation
- 2003-11-14 CA CA2506236A patent/CA2506236C/en not_active Expired - Lifetime
- 2003-11-14 US US10/493,558 patent/US20050090433A1/en not_active Abandoned
- 2003-11-14 PT PT03789744T patent/PT1565201T/pt unknown
- 2003-11-14 KR KR1020057008951A patent/KR101173310B1/ko active IP Right Grant
- 2003-11-14 US US10/713,924 patent/US20050004011A1/en not_active Abandoned
-
2004
- 2004-04-16 US US10/828,439 patent/US7115564B2/en not_active Expired - Lifetime
- 2004-04-16 US US10/828,379 patent/US20040220122A1/en not_active Abandoned
- 2004-04-16 US US10/828,483 patent/US20040198715A1/en not_active Abandoned
- 2004-04-20 US US10/829,068 patent/US20040224908A1/en not_active Abandoned
- 2004-09-15 US US10/942,197 patent/US20050032721A1/en not_active Abandoned
- 2004-09-15 US US10/942,604 patent/US20050130914A1/en not_active Abandoned
-
2005
- 2005-05-02 IL IL168327A patent/IL168327A/en active IP Right Grant
- 2005-05-12 NO NO20052362A patent/NO20052362L/no not_active Application Discontinuation
-
2006
- 2006-05-23 HK HK06105915A patent/HK1083684A1/xx not_active IP Right Cessation
-
2008
- 2008-08-19 HK HK08109254.4A patent/HK1114014A1/xx not_active IP Right Cessation
-
2009
- 2009-05-28 US US12/473,390 patent/US20090298748A1/en not_active Abandoned
- 2009-05-29 US US12/474,438 patent/US20090305953A1/en not_active Abandoned
-
2011
- 2011-04-05 JP JP2011083790A patent/JP2011157381A/ja active Pending
-
2013
- 2013-04-16 JP JP2013085785A patent/JP2013155188A/ja active Pending
-
2014
- 2014-02-06 IL IL230875A patent/IL230875A0/en unknown
-
2015
- 2015-07-13 IL IL239913A patent/IL239913B/en active IP Right Grant
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| DK1565201T3 (da) | Fremgangsmåder til at administrere dalbavancin til behandling af bakterieinfektioner | |
| CA2564112C (en) | Dalbavancin compositions for treatment of bacterial infections | |
| US20120184497A1 (en) | Dalbavancin compositions for treatment of bacterial infections | |
| ZA200503695B (en) | Methods of administering dalbavancin for treatment of bacterial infections |